Synthesis and biological evaluation as microtubule-active agents of several tetrahydrofuran and spiroacetal derivatives

Current Medicinal Chemistry

Volumn 20, Issue 9, 2013, Pages 1173-1182

  Carda, M ^a   Murga, J ^a   Panos J ^a   Angulo Pachon C A ^a   Garcia Pla J ^a   Diaz Oltra S ^a   Marco, J A ^b   Trigili, C ^c   Redondo Horcajo, M ^c   Diaz J F ^c   Barasoain, I ^c  

^a UNIVERSITAT JAUME I   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Anticancer Therapy; Antitumoral Drugs; Apoptosis; Bioactive Structural Fragments; Cytoskeleton; Cytotoxicity; Microtubule Disrupting Compounds; Microtubules; Spiroacetals; Tetrahydrofuran Derivatives; Tubulin

Indexed keywords

ACETAL DERIVATIVE; CYTOTOXIC AGENT; DOCETAXEL; PACLITAXEL; SPIROACETAL DERIVATIVE; TETRAHYDROFURAN DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IC 50; MICROTUBULE; MICROTUBULE ASSEMBLY; STEREOCHEMISTRY; SWERN OXIDATION;

ACETALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FURANS; HUMANS; LUNG; LUNG NEOPLASMS; MICROTUBULES; OVARIAN NEOPLASMS; OVARY; TUBULIN; TUBULIN MODULATORS;

EID: 84877972467     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320090006     Document Type: Article

References (85)

1. Fojo, T., Ed. The Role of Microtubules in Cell Biology, Neurobiology and Oncology; Humana Press: Totowa, New Jersey, 2008.
2. Amos, L. A. Microtubule structure and its stabilization. Org. Biomol. Chem., 2004, 2, 2153-2160.
3. Wade, R. H. On and around microtubules. Mol. Biotechnol., 2009, 43, 177-191.
4. Nogales, E.; Wang, H.-W. Structural intermediates in microtubule assembly and disassembly: how and why?. Curr. Opin. Cell Biol., 2006, 18, 179-184. (Pubitemid 43375886)
5. Nogales, E.; Wang, H.-W. Structural mechanisms underlying nucleotide-dependent self-Assembly of tubulin and its relatives. Curr. Opin. Struct. Biol., 2006, 16, 221-229.
6. Beckers, T.; Mahboobi, S. Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy. Drugs Fut., 2003, 28, 767-785. (Pubitemid 37345316)
7. Hadfield, J. A.; Ducki, S.; Hirst, N.; McGown, A. T. Tubulin and microtubules as targets for anticancer drugs. Progr. Cell Cycle Res., 2003, 5, 309-325.
8. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 2004, 4, 253-265. (Pubitemid 38525281)
9. Chen, S.-H.; Hong, J. Novel tubulininteracting agents: a tale of Taxus brevifolia and Catharanthus roseus-based drug discovery. Drugs Fut., 2006, 31, 123-150
10. Pasquier, E.; Kavallaris, M. Microtubules: a dynamic target in cancer therapy. IUBMB Life, 2008, 60, 165-170.
11. Singh, P.; Rathinasamy, K.; Mohan, R.; Panda, D. Microtubule assembly dynamics: an attractive target for anticancer drugs. IUBMB Life, 2008, 60, 368-375.
12. Morris, P. G.; Fornier, M. N. Microtubule active agents: beyond the taxane frontier. Clin. Cancer Res., 2008, 14, 7167-7172.
13. Perez, E. A. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol. Cancer Ther., 2009, 8, 2086-2095.
14. Chen, S. M.; Meng, L.-H.; Ding, J. New microtubuleinhibiting anticancer agents. Expert Opin. Invest. Drugs, 2010, 19, 329-343.
15. Calligaris, D.; Verdier-Pinard, P.; Devred, F.; Villard, C.; Braguer, D.; Lafitte, D. Microtubule targeting agents: from biophysics to proteomics. Cell. Mol. Life Sci., 2010, 67, 1089-1104.
16. Goyal, S. S.; Patel, R. M.; Sukhramani, P. S.; Kamothi, K. A. Microtubules: a novel target for cancer therapy. Int. J. Pharm. Sci. Res., 2010, 1, 1-21.
17. For a review, see: Portt, L.; Norman, G.; Clapp, C.; Greenwood, M.; Greenwood, M. T. Anti-Apoptosis and cell survival: A review. Biochim. Biophys. Acta, 2011, 1813, 238-259.
18. See also: Llovera, L.; Mansilla, S.; Portugal, J. Apoptotic-like death occurs through a caspase-independent route in colon carcinoma cells undergoing mitotic catastrophe. Cancer Lett. 2012, 326, 114-121.
19. Altmann, K.-H.; Gertsch, J. Anticancer drugs from Nature natural products as a unique source of new microtubulestabilizing agents. Nat. Prod. Rep., 2007, 24, 327-357. (Pubitemid 46504987)
20. Kingston, D. G. I. A natural love of natural products. J. Org. Chem., 2008, 73, 3975-3984. (Pubitemid 351812897)
21. Kingston, D. G. I. Tubulin-interactive natural products as anticancer agents. J. Nat. Prod., 2009, 72, 507-515.
22. Chen, J.; Liu, T.; Dong, X.; Hu, Y. Recent development and SAR analysis of colchicine binding site inhibitors. Mini-Rev. Med. Chem., 2009, 9, 1174-1190.
23. Fu, Y.; Li, S.; Zu, Y.; Yang, G.; Yang, Z.; Luo, M.; Jiang, S.; Wink, M.; Efferth, T. Medicinal chemistry of paclitaxel and its analogs. Curr. Med. Chem., 2009, 16, 3966-3985.
24. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem.Anticancer Drugs, 2002, 2, 1-17. (Pubitemid 34649866)
25. Abal, M.; Andreu, J. M.; Barasoain, I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr. Cancer Drug Targets, 2003, 3, 193-203. (Pubitemid 36565761)
26. Correia, J. J.; Lobert, S. Physiochemical aspects of tubulininteracting antimitotic drugs. Curr. Pharm. Des., 2001, 7, 1213-1228. (Pubitemid 32798805)
27. Jiménez-Barbero, J.; Amat-Guerri, F.; Snyder, J. P. The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization. Curr. Med. Chem.Anticancer Drugs, 2002, 2, 91-122. (Pubitemid 34649870)
28. Díaz, J. F.; Andreu, J. M.; Jiménez-Barbero, J. The interaction of microtubule with stabilizers characterized at biochemical and structural levels. Top. Curr. Chem., 2009, 286, 121-149.
29. Gigant, B.; Cormier, A.; Dorléans, A.; Ravelli, R. B. G.; Knossow, M. Microtubule-destabilizing agents: structural and mechanistic insights from the interaction of colchicine and vinblastine with tubulin. Top. Curr. Chem., 2009, 286, 259-278.
30. Daly, E. M.; Taylor, R. E. Entropy and enthalpy in the activity of tubulin-based antimitotic agents. Curr. Chem. Biol., 2009, 3, 367-379.
31. Sánchez-Pedregal, V. M.; Griesinger, C. The tubulin binding mode of MT stabilizing and destabilizing agents studied by NMR. Top. Curr. Chem., 2009, 286, 151-208.
32. Nettles, J. H.; Downing, K. H. The tubulin binding mode of microtubule stabilizing agents studied by electron crystallography. Top. Curr. Chem., 2009, 286, 209-257.
33. Botta, M.; Forli, S.; Magnani, M.; Manetti, F. Molecular modeling approaches to study the binding mode on tubulin of microtubule destabilizing and stabilizing agents. Top. Curr. Chem., 2009, 286,279-328.
34. Sarabia, F.; García-Castro, M.; Sánchez-Ruiz, A. Chemistry and biology of novel microtubule-destabilizing agents that bind -Tubulin. Curr. Bioact. Comp., 2006, 2, 269-299.
35. Anderson, H. J.; Coleman, J. E.; Andersen, R. J.; Roberge, M. Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother. Pharmacol., 1997, 39, 223-226. (Pubitemid 26414259)
36. Kondoh, M.; Usui, T.; Kobayashi, S.; Tsuchiya, K; Nishikawa, K.; Nishikiori, T.; Mayumi, T.; Osada, H. Cell cycle arrest and antitumor activity of pironetin and its derivatives. Cancer Lett., 1998, 126, 29-32. (Pubitemid 28142968)
37. Kondoh, M.; Usui, T.; Nishikiori, T.; Mayumi, T.; Osada, H. Apoptosis induction via microtubule disassembly by an antitumour compound, pironetin. Biochem. J., 1999, 340, 411-416. (c) Watanabe, H.; Watanabe, H.; Usui, T.; Kondoh, M.; Osada, H.; Kitahara, T. Synthesis of pironetin and related analogs: studies on structure-Activity relationships as tubulin assembly inhibitors. J. Antibiot., 2000, 53, 540-545.
38. Usui, T.; Watanabe, H.; Nakayama, H.; Tada, Y.; Kanoh, N.; Kondoh, M.; Asao, T.; Takio, K.; Watanabe, H.; Nishikawa, K.; Kitahara, T.; Osada, H. The anticancer natural product pironetin selectively targets Lys352 of -Tubulin. Chem. & Biol., 2004, 11, 799-806. (Pubitemid 38836896)
39. Yasui, K.; Tamura, Y.; Nakatani, K.; Kawada, K.; Ohtani, M. Total Synthesis of ()-PA-48153C, a novel immunosuppressive 2-pyranone derivative. J. Org. Chem., 1995, 60, 7567-7574.
40. Gurjar, M. K.; Henri, J. T. Jr.; Bose, D. S.; Rao, A. V. R. Total synthesis of a potent immunosuppressant pironetin. Tetrahedron Lett., 1996, 37, 6615-6618. (Pubitemid 26278302)
41. Chida, N.; Yoshinaga, M.; Tobe, T.; Ogawa, S. Total synthesis of ()-PA-48153C (pironetin) utilising l quebrachitol as a chiral building block. Chem. Comm., 1997, 1043-1044. (Pubitemid 27246502)
42. Watanabe, H.; Watanabe, H.; Bando, M.; Kido, M.; Kitahara, T. An efficient synthesis of pironetins employing a useful chiral building block, (1S,5S,6R)-5-hydroxybicyclo[4.1.0]heptan-2-one. Tetrahedron, 1999, 55, 9755-9776. (Pubitemid 29366849)
43. Keck, G. E.; Knutson, C. E.; Wiles, S. A. Total synthesis of the immunosupressant ()-pironetin (PA48153C). Org. Lett., 2001, 3, 707-710. (Pubitemid 33627016)
44. Dias, L. C.; de Oliveira, L. G.; de Sousa, M. A. Total synthesis of ()-pironetin. Org. Lett., 2003, 5, 265-268.
45. Shen, X.; Wasmuth, A. S.; Zhao, J.; Zhu, C.; Nelson, S. G. Catalytic asymmetric assembly of stereodefined propionate units: an enantioselective total synthesis of ()-pironetin. J. Am. Chem. Soc., 2006, 128, 7438-7439. (Pubitemid 43877507)
46. Enders, D.; Dhulut, S.; Steinbusch, D.; Herrbach, A. Asymmetric total synthesis of ()-pironetin employing the SAMP/RAMP hydrazone methodology. Chem. Eur. J., 2007, 13, 3942-3949. (Pubitemid 46925605)
47. Bressy, C.; Vors, J.-P.; Hillebrand, S.; Arseniyadis, S.; Cossy, J. Asymmetric total synthesis of the immunosuppressant ()-pironetin. Angew. Chem. Int. Ed., 2008, 47, 10137-10140.
48. Crimmins, M. T.; Dechert, A.-M. R. Enantioselective total synthesis of ()-pironetin: iterative aldol reactions of thiazolidinethiones. Org. Lett., 2009, 11, 1635-1638.
49. Vogt, A.; McPherson, P. A.; Shen, X.-Q.; Balachandran, R.; Zhu, G.-Y.; Raccor, B. S.; Nelson, S. G.; Tsang, M.; Day, B. W. High-content analysis of cancer-cell-specific apoptosis and inhibition of in vivo angiogenesis by synthetic ()-pironetin and analogs. Chem. Biol. Drug Des., 2009, 74, 358-368.
50. Lin, J.; Yue, X.; Huang, P.; Cui, D.; Qing, F.-L. Synthesis of gemdifluoromethylenated analogs of pironetin. Synlett, 2010, 267-275.
51. Uckun, F. M.; Mao, C.; Jan, S.-T.; Huang, H.; Vassilev, A. O.; Sudbeck, E. A.; Navara, C. S.; Narla, R. K. SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity. Curr. Opin. Invest. Drugs, 2000, 1, 252-256.
52. Uckun, F. M.; Sudbeck, E. A.; Mao, C.; Ghosh, S.; Liu, X. P.; Vassilev, A.O.; Navara, C. S.; Narla, R. K. Structure-based design of novel anticancer agents. Curr. Cancer Drug Targ., 2001, 1, 59-71. (Pubitemid 33772175)
53. Uckun, F. M.; Mao, C.; Vassilev, A. O.; Navara, C.S.; Narla, R. K.; Jan, S.-T. A rationally designed anticancer drug targeting a unique binding cavity of tubulin. Bioorg. Med. Chem. Lett., 2000, 10, 1015-1018. Compound COBRA-0 is named WHI-261 in this paper. (Pubitemid 30406455)
54. Jan, S.-T.; Mao, C.; Vassilev, A. O.; Navara, C. S.; Uckun, F. M. COBRA-1, a rationally-designed epoxy-THF containing compound with potent tubulin depolymerizing activity as a novel anticancer agent. Bioorg. Med. Chem. Lett., 2000, 10, 1193-1197. (Pubitemid 30345089)
55. Uckun, F. M.; Mao, C.; Jan, S.-T.; Huang, H.; Vassilev, A. O.; Navara, C. S.; Narla, R. K. Spongistatins as tubulin targeting agents. Curr. Pharm. Des., 2001, 7, 1291-1296. (Pubitemid 32798810)
56. Uckun, F. M. Rationally designed anti-mitotic agents with pro-Apoptotic activity. Curr. Pharm. Des., 2001, 7, 1627-1639. (Pubitemid 32998575)
57. Gerber-Lemaire, S.; Vogel, P. Spongistatins: biological activity and synthetic studies. Compt. Rend. Chimie, 2008, 11, 1382-1418.
58. Smith, A. B., III; Risatti, C.; Atasoylu, O.; Bennett, C. S.; Liu, J.; Cheng, H.; Ten Dyke, K.; Xu, Q. Design, synthesis, and biological evaluation of diminutive forms of (+)-spongistatin 1: lessons learned. J. Am. Chem. Soc., 2011, 133, 14042-14053.
59. For reviews on natural products containing spiroacetal fragments and methods for the synthesis of such functional moieties, see: (a) Perron, F.; Albizati, K. F. Chemistry of spiroacetals. Chem. Rev., 1989, 89, 1617-1661.
60. Brimble, M. A.; Farés, F. A. Synthesis of bis-spiroacetal ring systems. Tetrahedron, 1999, 55, 7661-7706 (Pubitemid 29272307)
61. Aho, J. E.; Pihko, P. M.; Rissa, T. K. Nonanomeric spiroacetals in natural products: structures, sources, and synthetic strategies. Chem. Rev., 2005, 105, 4406-4440. (Pubitemid 43091992)
62. Pettit, G. R.; Cichacz, Z. A.; Gao, F.; Herald, C. L.; Boyd, M. R.; Schmidt, J. M.; Hooper, J. N. A. Antineoplastic agents. 257. Isolation and structure of spongistatin-1. J. Org. Chem., 1993, 58, 1302-1304.
63. Uckun, F. M.; Mao, C.; Vassilev, A.O.; Huang, H.; Jan, S.-T. Structure-based design of a novel synthetic spiroacetal pyran as a pharmacophore for the marine natural product spongistatin 1. Bioorg. Med. Chem. Lett., 2000, 10, 541-545. (Pubitemid 30162456)
64. Smith, A. B., III; Corbett, R. M.; Pettit, G. R.; Chapuis, J.-C.; Schmidt, J. M.; Hamel, E.; Jung, M. K. Synthesis and biological evaluation of a spongistatin AB-spiroacetal analog. Bioorg. Med. Chem. Lett., 2002, 12, 2039-2042. (Pubitemid 34756477)
65. Marco, J. A.; García-Pla, J.; Carda, M.; Murga, J.; Falomir, E.; Trigili, C.; Notararigo, S.; Díaz, J. F.; Barasoain, I. Design and synthesis of pironetin analogs with simplified structure and study of their interactions with microtubules. Eur. J. Med. Chem., 2011, 46, 1630-1637.
66. Jan, S.-T.; Li, K.; Vig, S.; Rudolph, A.; Uckun, F. M. Stereoselective synthesis of a versatile intermediate for the total synthesis of mono-And bis-THF containing annonaceous acetogenins. Tetrahedron Lett., 1999, 40, 193-196. (Pubitemid 29010580)
67. Lipshutz, B. H.; Sengupta, S. Organocopper reagents: substitutions, conjugate additions, carbo/metallocuprations and other reactions. Org. React., 1992, 41, 135-631.
68. Krause, N., Ed. Modern Organocopper Chemistry; Wiley-VCH: Weinheim, Germany, 2004.
69. Zhang, J.; Li, Y.; Wang, W.; She, X.; Pan, X. Concise asymmetric total synthesis of obolactone. J. Org. Chem., 2006, 71, 2918-2921.
70. Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 3rd Ed.; John Wiley and Sons: New York, 1999; pp. 45-48.
71. Tsuji, J. In: Addition reactions with formation of carbon-oxygen bonds (iv): the Wacker oxidation and related reactions. Comprehensive Organic Synthesis; Trost, B. M.; Fleming, I.; Winterfeldt, E., Eds.; Pergamon Press, Oxford, 1993, vol. 7, pp. 449-468
72. Takacs, J. M., Jiang, X.-T. The Wacker reaction and related alkene oxidation reactions. Curr. Org. Chem., 2003, 7, 369-396. (Pubitemid 36221406)
73. Cornell, C. N., Sigman, M. S. Recent progress in Wacker oxidations: moving toward molecular oxygen as the sole oxidant. Inorg. Chem., 2007, 46, 1903-1909.
74. Mancuso, A. J.; Swern, D. Activated dimethyl sulfoxide: useful reagents for synthesis. Synthesis, 1981, 165-185.
75. Tidwell, T. T. Oxidations of alcohols to carbonyl compounds with alkoxysulfonium ylides: the Moffatt, Swern, and related oxidations. Org. React., 1990, 39, 297-572.
76. Cowden, C. J.; Paterson, I. Asymmetric aldol reactions using boron enolates. Org. React., 1997, 51, 1-200.
77. The aldol addition of the enolborane of -Alkoxy methyl ketone 13 to aldehyde 16 took place with moderate 1,5-Anti selectivity. This remote induction has previously been observed by Evans and coworkers in related cases: Evans, D. A.; Coté, B.; Coleman, P. J.; Connell, B. T. 1,5-Asymmetric induction in boron-mediated -Alkoxy methyl ketone aldol addition reactions. J. Am. Chem. Soc., 2003, 125, 10893-10898. In contrast, the aldol addition of the enolborane of -Alkoxy methyl ketone 13 to aldehyde ent-16 took place with moderate 1,5-syn selectivity (see Supplementary Material). (Pubitemid 37087547)
78. For a review on this type of aldol reactions, see: Dias, L. C.; Aguilar, A. M. 1,5-Asymmetric induction in boron-mediated aldol reactions of -oxygenated methyl ketones. Chem. Soc. Rev., 2008, 37, 451-469.
79. Oosawa, F.; Asakura, S. Thermodynamics of the Polymerization of Proteins. Academic Press, London, 1975.
80. For a NMR study of the solution conformation of spongistatin 1, aided by computational calculations, see: Atasoylu, O.; Furst, G.; Risatti, C.; Smith, A. B., III. The solution structure of (+)-spongistatin 1 in DMSO. Org. Lett., 2010, 12, 1788-1791.
81. For a recent synthesis of the spiroacetal fragments of spongistatin 1, see: Flowers, C. L.; Vogel, P. Short diastereoselective synthesis of the C1-C13 (AB spiroacetal) and C17-C28 fragments (CD spiroacetal) of spongistatin 1 and 2 through double chain-elongation reactions. Chem. Eur. J., 2010, 16, 14074-14082.
82. Buey, R. M.; Calvo, E.; Barasoain, I.; Pineda, O.; Edler, M. C.; Matesanz, R.; Cerezo, G.; Vanderwal, C. D.; Day, B. W.; Sorensen, E. J.; López, J. A.; Andreu, J. M.; Hamel, E.; Díaz, J. F. Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites. Nature Chem Biol., 2007, 3, 117-125. (Pubitemid 46134999)
83. Yang, C.; Barasoain, I.; Li, X.; Matesanz, R.; Liu, R.; Sharom, F. J.; Yin, D. L.; Díaz, J. F.; Fang, W. S. Overcoming tumor drug resistance mediated by P-glycoprotein overexpression with high affinity taxanes: A SAR study of C-2 modified 7-Acyl-10-deacetylcephalomannines. ChemMedChem., 2007, 2, 691-701.
84. De Ines, C.; Leynadier, D.; Barasoain, I.; Peyrot, V.; Garcia, P.; Briand, C.; Rener, G. A.; Temple, C. Jr. Inhibition of microtubules and cell-cycle arrest by a new 1-deaza-7,8-dihydropteridine antitu mor drug, CI-980, and by its chiral isomer, NSC-613863. Cancer Res., 1994, 54, 75-84. (Pubitemid 24979983)
85. Buey, R. M.; Barasoain, I.; Jackson, E.; Meyer, A.; Giannakakou, P.; Paterson, I.; Mooberry, S.; Andreu, J. M.; Díaz, J. F. Microtubule interactions with chemically diverse stabilizing agents: Thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chem. Biol., 2005, 12, 1269-1279. (Pubitemid 41779467)